GKB65.00

GKB Ophthalmics Limited

· Pharma & Health
₹ CrorePeersFABTECHLAXMIDENTLTARSONSFISCHER
Comp Set
In ₹ Crore except Per Share
Latest Annual
GKB
FY23
FABTECH
FY26
LAXMIDENTL
FY26
TARSONS
FY26
Peer
Median
Valuation — at last close
P/E14.71×36.76×118.59×36.76×
P/B1.56×4.58×2.67×2.67×
EV/EBITDA17.14×25.26×17.44×17.44×
Market Cap₹654 Cr₹1,117 Cr₹1,697 Cr₹1,117 Cr
Growth
Revenue YoY (latest Q)10.26%13.87%20.66%13.87%
Net Income YoY (latest Q)168.73%23.83%-180.99%23.83%
Profitability
EBITDA Margin-3.95%8.52%15.62%27.91%15.62% -125%
Net Income Margin-10.39%9.34%10.41%3.39%9.34% -211%
Return on Common Equity-10.47%9.14%11.87%2.26%9.14% -215%
Return on Capital Employed-11.50%6.65%10.46%2.32%6.65% -273%
Return on Assets-5.86%5.87%9.84%1.21%5.87% -200%
Credit & Quality
Total Debt/Equity0.41×0.10×0.00×0.60×0.10× +310%
Interest Coverage-2.43×7.14×20.15×0.95×7.14× -134%
Scale — latest FY
Revenue / Total Income₹27.7 Cr₹411 Cr₹278 Cr₹423 Cr₹411 Cr -93%
Net Income−₹2.9 Cr₹38.4 Cr₹28.9 Cr₹14.3 Cr₹28.9 Cr -110%
Total Assets₹49.1 Cr₹654 Cr₹294 Cr₹1,186 Cr₹654 Cr -92%
EPS₹-5.72₹10₹5.53₹2.69₹5.53 -203%
Book Value per Share₹94.43₹44.42₹119.29₹94.43
◆ best value in the comp set per metric · Δ = subject vs median of the other companies.
« ‹ › »Latest: FY23 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 85%.